What is a papillary tumour of the pineal region?
A papillary tumour of the pineal region (PTPR) is a rare brain tumour that grows in the pineal region, a small area deep in the centre of the brain. This area contains the pineal gland, the fluid channels that drain the brain and the upper part of the brainstem. Despite its location, PTPR does not seem to come from the pineal gland itself.
Researchers believe PTPR arises from a tiny, specialised structure nearby called the subcommissural organ. This structure is lined by cells similar to ependymal cells, the cells that line the brain’s fluid spaces (Fevre Montange et al., 2015). Under the microscope, the tumour forms finger-like projections (papillae), which gives it its name.
PTPR was first described as a separate tumour in 2003 and was added to the World Health Organization (WHO) classification of brain tumours in 2007. It is graded as WHO CNS grade 2 or 3. It mostly affects young and middle-aged adults, although children can also be affected.
The usual first symptoms come from hydrocephalus, a build-up of fluid caused by the tumour blocking fluid flow. Treatment is mainly surgery, often followed by radiotherapy. The tumour has a strong tendency to come back locally, so long-term follow-up is essential, but many people live for many years (Lancia et al., 2020).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of tumour | Neuroepithelial tumour with ependymal-like features, WHO CNS grade 2 or 3 |
| Where it grows | Pineal region, near the back of the third ventricle |
| Probable origin | Subcommissural organ |
| Typical age | Young adults; mean age about 33 years in pooled data |
| Sex | Roughly equal in men and women |
| Main symptoms | Headache and other signs of hydrocephalus |
| Main treatment | Surgery, often with radiotherapy |
| Recurrence | Common; more than half recur within 5 years |
| Outlook | Most patients alive at 3 years; long-term survival is possible |
2. Types
Molecular subtypes
A study of 76 tumours confirmed by DNA methylation profiling identified three molecular subtypes (Wu et al., 2024).
| Subtype | Features |
|---|---|
| PTPR-A | One of the two main methylation groups |
| PTPR-B1 | Frequent loss of chromosome 3 or 14 |
| PTPR-B2 | No such chromosome losses |
Nearly half of the patients whose outcomes were examined had tumour progression, and the risk differed between subtypes. These subtypes may help predict behaviour in future, but are not yet used routinely to choose treatment.
Other tumours in the pineal region
| Tumour | How it differs |
|---|---|
| Pineocytoma | Slow-growing tumour of the pineal gland itself |
| Pineal parenchymal tumour of intermediate differentiation | Arises from pineal cells; KBTBD4 gene changes |
| Pineoblastoma | Aggressive, mostly in children |
| Germ cell tumours | Teenagers and young adults; tumour markers may be raised |
| Papillary ependymoma | Similar features, but different location and genetics |
| Choroid plexus papilloma | Papillary tumour of the fluid-producing tissue |
| Metastatic carcinoma | Spread from cancer elsewhere, in older adults |
Several of these can look similar under the microscope, so specialist pathology review is important (Fevre Montange et al., 2015).
Why grading is difficult
Exact rules for grading PTPR have not yet been fully defined (Fevre Montange et al., 2015). Pathologists look at how often the cells divide, whether there is dead tissue and how quickly the cells are growing, but these features do not always predict behaviour. This is one reason why research has turned to molecular subtypes, which may in future give a more reliable guide to the risk of recurrence.
3. Causes and risk factors
The cause of PTPR is unknown.
| Factor | Notes |
|---|---|
| Age | Most common in the third and fourth decades |
| Sex | No strong preference |
| Inherited conditions | None known |
| Lifestyle or environment | No known link |
| Genetic changes in the tumour | Acquired changes, including chromosome losses; not inherited |
4. How does it look
On scans
| Feature | Typical finding |
|---|---|
| Location | Pineal region, at the back of the third ventricle |
| Borders | Well-defined |
| Content | Solid, often with cystic areas |
| MRI signal | May show bright areas on T1 images before contrast |
| Contrast enhancement | Usually present |
| Hydrocephalus | Common |
Under the microscope
| Feature | Description |
|---|---|
| Architecture | Papillae with blood vessels at their core |
| Cells | Column-shaped or cube-shaped cells in several layers |
| Pseudorosettes | Cells arranged around blood vessels |
| Cytokeratin staining | Strongly positive, especially cytokeratin 18 |
| Electron microscopy | Features of ependymal cells, such as many microvilli |
| Methylation profiling | Confirms the diagnosis in difficult cases |
5. Symptoms
Common symptoms
In pooled data, raised pressure in the head and hydrocephalus were the main clinical picture (Yamaki et al., 2019). Symptoms include:
- Headache, often worse on waking
- Nausea and vomiting
- Blurred or double vision
- Difficulty looking upwards
- Unsteady walking
Less common symptoms
| Symptom | Possible cause |
|---|---|
| Drowsiness | Severe hydrocephalus |
| Memory or concentration problems | Raised pressure |
| Pupils that react poorly to light | Pressure on the midbrain |
| Hormonal changes | Rare effects on nearby structures |
| Back pain or leg symptoms | Spread to the spine, which is uncommon |
When to seek urgent help
Seek urgent medical attention for a sudden or severe headache with vomiting, drowsiness, confusion or sudden visual loss.
6. Diagnosis
| Test | Purpose |
|---|---|
| MRI of the brain with contrast | Shows the tumour and fluid blockage |
| MRI of the spine | Checks for spread |
| Tumour markers in blood and spinal fluid | Help exclude germ cell tumours |
| Endoscopic biopsy | Can be combined with treatment of hydrocephalus |
| Surgical removal | Provides the full tumour for diagnosis |
| Specialist pathology review | Distinguishes PTPR from similar tumours |
| DNA methylation profiling | Confirms the diagnosis and subtype |
Treatment of hydrocephalus
| Procedure | Notes |
|---|---|
| Endoscopic third ventriculostomy | Creates a bypass for fluid; allows a biopsy |
| Shunt | Drains fluid to the abdomen |
| Temporary external drain | Used in emergencies |
7. Treatment
There is no standard treatment proven by trials. Plans are based on pooled case reports and series and on expert consensus (Liu et al., 2024).
Surgery
| Aspect | Details |
|---|---|
| Aim | Remove as much tumour as safely possible |
| How often performed | About 82% of patients in pooled data |
| Complete removal achieved | In about 71% of those operated |
| Effect on survival | Having surgery was linked with better 3-year survival (Yamaki et al., 2019) |
Interestingly, the same analysis did not show a clear additional survival benefit from complete removal compared with partial removal. Even so, most surgeons aim for the safest maximal removal.
Radiotherapy
| Aspect | Details |
|---|---|
| How often used | About 72% of patients in a review of published cases |
| Conventional dose | Between 45 Gy and 60 Gy in daily fractions |
| Stereotactic radiosurgery dose | Between 12 Gy and 36 Gy |
| Side effects | Treatment-related toxicity was very limited in the review |
Because PTPR is considered a grade 2 or 3 tumour, reviewers suggested a higher total dose after surgery (Lancia et al., 2020). Radiotherapy is also used for recurrent tumours.
Chemotherapy
Chemotherapy has a limited, uncertain role. It may be considered for tumours that keep returning or spread, usually in a clinical trial or after specialist discussion.
Treatment by situation
| Situation | Typical approach |
|---|---|
| Newly diagnosed, removable | Surgery, then focal radiotherapy in many cases |
| Small residual tumour | Focal radiotherapy or radiosurgery |
| Local recurrence | Further surgery, radiotherapy or radiosurgery |
| Spread along the spine | Radiotherapy to affected areas; chemotherapy considered |
What a treatment journey may look like
| Step | What happens | Typical timing |
|---|---|---|
| Emergency care | Treatment of hydrocephalus, steroids for swelling | First days |
| Planning | Specialist MRI, tumour markers, multidisciplinary meeting | 1-2 weeks |
| Surgery | Removal through the back of the head | Within weeks |
| Pathology results | Microscope, staining and molecular tests | 2-4 weeks after surgery |
| Radiotherapy | Daily weekday sessions | About 5-6 weeks, starting 4-8 weeks after surgery |
| Rehabilitation | Eye, balance and fatigue support | Months |
PTPR in children
PTPR is less common in children than in adults. Paediatric teams aim to limit radiotherapy where possible, because of its effects on the developing brain, growth and hormones. Children often need support with schooling and learning after treatment, and long-term follow-up continues into adulthood.
Side effects
| Treatment | Possible side effects |
|---|---|
| Surgery | Double vision, upward-gaze problems, balance difficulties, bleeding, infection |
| Radiotherapy | Tiredness, hair loss in the treated area, memory changes, hormone problems |
| Radiosurgery | Swelling around the treated area, headache |
| Shunt | Blockage or infection, requiring revision |
8. Outlook (prognosis)
| Measure | Result |
|---|---|
| 3-year survival (pooled data) | About 84% |
| Local recurrence by 5 years | About 60% |
| Local recurrence by 10 years | More than 80% |
| Expected 10-year overall survival | About 73% |
| Median time to recurrence | About 29 months |
These figures come from Yamaki et al. (2019) and Lancia et al. (2020). In the pooled analysis, larger tumour size was linked with poorer survival, while having surgery was linked with better survival.
Good functional outcomes
About six in ten patients in the pooled analysis had a good functional outcome, able to live independently (Yamaki et al., 2019). Recurrence does not always mean a poor result, because repeat surgery and radiotherapy can often control it.
9. Follow-up
| Time | Typical checks |
|---|---|
| First 2 years | Brain MRI every 3-6 months |
| Years 3-5 | MRI every 6 months |
| After 5 years | Yearly MRI, continuing long term |
| Spine MRI | If symptoms or brain findings suggest spread |
| Other checks | Eye, hormone and memory assessments |
Follow-up is lifelong in many cases, because recurrence can occur late.
10. Living with a papillary tumour of the pineal region
- Keep all scan appointments, even when you feel well
- Know the signs of shunt problems, such as headache, vomiting and drowsiness
- Get help for vision problems from an orthoptist or eye specialist
- Return to activities gradually, and ask about a phased return to work
- Check driving rules with your doctor before driving
- Keep a symptom diary to share with your team at follow-up visits
- Seek support from brain tumour charities and counselling services
Living with a shunt
| Topic | Advice |
|---|---|
| Warning signs of blockage | Headache, vomiting, drowsiness, blurred vision; seek help urgently |
| Signs of infection | Fever, redness along the tubing, abdominal pain |
| Programmable valves | Strong magnets, including some MRI scanners, can change settings; tell staff you have one |
| Activities | Most normal activities are possible; ask about contact sports |
| Travel | Carry details of your shunt and your neurosurgical centre |
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is it cancer? | It is a grade 2 or 3 brain tumour that can recur, but it rarely spreads outside the brain and spine |
| Is it a tumour of the pineal gland? | No; it grows next to the gland, probably from the subcommissural organ |
| Why does it come back so often? | Its location makes complete removal difficult, and cells can remain |
| Will I need radiotherapy? | Many people do, especially after partial removal |
| Can a recurrence be treated? | Yes, with further surgery or radiotherapy in many cases |
| Is it inherited? | No |
| Will I need a shunt? | Only if fluid blockage cannot be relieved by other means |
| How long will follow-up last? | Usually many years, often for life |
| Can I have children after treatment? | Usually yes; ask about hormone checks if radiotherapy affected the pituitary region |
12. Questions to ask your care team
- Has the diagnosis been confirmed by a specialist neuropathologist?
- Was methylation testing done?
- How much of the tumour was removed?
- Do you recommend radiotherapy now or only if it grows?
- What are the signs of recurrence I should watch for?
- How often will I have scans?
- Who should I contact if I develop new headaches?
- What rehabilitation services are available?
Resources
- Fevre Montange, M. et al. (2015) ‘Papillary tumor of the pineal region: histopathological characterization and review of the literature’, Neurochirurgie, 61(2-3), pp. 138-142.
- Lancia, A. et al. (2020) ‘Radiotherapy for papillary tumor of the pineal region: a systematic review of the literature’, Clinical Neurology and Neurosurgery, 190, 105646.
- Liu, A.P.Y. et al. (2024) ‘SNO-EANO-EURACAN consensus on management of pineal parenchymal tumors’, Neuro-Oncology, 26(12), pp. 2159-2173.
- Wu, Z. et al. (2024) ‘Papillary tumor of the pineal region: analysis of DNA methylation profiles and clinical outcomes in 76 cases’, Acta Neuropathologica Communications, 12(1), 117.
- Yamaki, V.N. et al. (2019) ‘Papillary tumor of the pineal region: systematic review and analysis of prognostic factors’, Neurosurgery, 85(3), pp. E420-E429.
- National Cancer Institute (2026) Adult Central Nervous System Tumors Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.